280 related articles for article (PubMed ID: 27493709)
1. Elotuzumab: the first approved monoclonal antibody for multiple myeloma treatment.
Magen H; Muchtar E
Ther Adv Hematol; 2016 Aug; 7(4):187-95. PubMed ID: 27493709
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and safety of elotuzumab for the treatment of multiple myeloma.
Gavriatopoulou M; Terpos E; Kastritis E; Dimopoulos MA
Expert Opin Drug Saf; 2017 Feb; 16(2):237-245. PubMed ID: 28060563
[TBL] [Abstract][Full Text] [Related]
3. Emerging combination therapies for the management of multiple myeloma: the role of elotuzumab.
Chen WC; Kanate AS; Craig M; Petros WP; Hazlehurst LA
Cancer Manag Res; 2017; 9():307-314. PubMed ID: 28744161
[TBL] [Abstract][Full Text] [Related]
4. Mechanisms of NK Cell Activation and Clinical Activity of the Therapeutic SLAMF7 Antibody, Elotuzumab in Multiple Myeloma.
Campbell KS; Cohen AD; Pazina T
Front Immunol; 2018; 9():2551. PubMed ID: 30455698
[TBL] [Abstract][Full Text] [Related]
5. Elotuzumab with lenalidomide and dexamethasone for Japanese patients with relapsed/refractory multiple myeloma: phase 1 study.
Iida S; Nagai H; Kinoshita G; Miyoshi M; Robbins M; Pandya D; Bleickardt E; Chou T
Int J Hematol; 2017 Mar; 105(3):326-334. PubMed ID: 27848182
[TBL] [Abstract][Full Text] [Related]
6. Elotuzumab in combination with lenalidomide and dexamethasone in patients with relapsed multiple myeloma: final phase 2 results from the randomised, open-label, phase 1b-2 dose-escalation study.
Richardson PG; Jagannath S; Moreau P; Jakubowiak AJ; Raab MS; Facon T; Vij R; White D; Reece DE; Benboubker L; Zonder J; Tsao LC; Anderson KC; Bleickardt E; Singhal AK; Lonial S;
Lancet Haematol; 2015 Dec; 2(12):e516-27. PubMed ID: 26686406
[TBL] [Abstract][Full Text] [Related]
7. Update on elotuzumab, a novel anti-SLAMF7 monoclonal antibody for the treatment of multiple myeloma.
Lonial S; Kaufman J; Reece D; Mateos MV; Laubach J; Richardson P
Expert Opin Biol Ther; 2016 Oct; 16(10):1291-301. PubMed ID: 27533882
[TBL] [Abstract][Full Text] [Related]
8. Elotuzumab for the Treatment of Relapsed or Refractory Multiple Myeloma, with Special Reference to its Modes of Action and SLAMF7 Signaling.
Taniwaki M; Yoshida M; Matsumoto Y; Shimura K; Kuroda J; Kaneko H
Mediterr J Hematol Infect Dis; 2018; 10(1):e2018014. PubMed ID: 29531651
[TBL] [Abstract][Full Text] [Related]
9. Treatment of multiple myeloma with the immunostimulatory SLAMF7 antibody elotuzumab.
Einsele H; Schreder M
Ther Adv Hematol; 2016 Oct; 7(5):288-301. PubMed ID: 27695618
[TBL] [Abstract][Full Text] [Related]
10. The role of elotuzumab in the treatment of relapsed or refractory multiple myeloma.
Comeau JM; Kelly K; Jean GW
Am J Health Syst Pharm; 2018 Jan; 75(2):55-66. PubMed ID: 29317395
[TBL] [Abstract][Full Text] [Related]
11. Monoclonal Antibodies in Multiple Myeloma: A New Wave of the Future.
Sherbenou DW; Mark TM; Forsberg P
Clin Lymphoma Myeloma Leuk; 2017 Sep; 17(9):545-554. PubMed ID: 28734795
[TBL] [Abstract][Full Text] [Related]
12. Update on elotuzumab for the treatment of relapsed/refractory multiple myeloma: patients' selection and perspective.
Trudel S; Moreau P; Touzeau C
Onco Targets Ther; 2019; 12():5813-5822. PubMed ID: 31410026
[TBL] [Abstract][Full Text] [Related]
13. A review discussing elotuzumab and its use in the second-line plus treatment of multiple myeloma.
Offidani M; Corvatta L
Future Oncol; 2018 Feb; 14(4):319-329. PubMed ID: 29091475
[TBL] [Abstract][Full Text] [Related]
14. Elotuzumab: A Review in Relapsed and/or Refractory Multiple Myeloma.
Lamb YN
Drugs; 2018 Sep; 78(14):1481-1488. PubMed ID: 30232695
[TBL] [Abstract][Full Text] [Related]
15. Preclinical and clinical evaluation of elotuzumab, a SLAMF7-targeted humanized monoclonal antibody in development for multiple myeloma.
Palumbo A; Sonneveld P
Expert Rev Hematol; 2015 Aug; 8(4):481-91. PubMed ID: 26070331
[TBL] [Abstract][Full Text] [Related]
16. Immunotherapy: A New Approach to Treating Multiple Myeloma with Daratumumab and Elotuzumab.
Afifi S; Michael A; Lesokhin A
Ann Pharmacother; 2016 Jul; 50(7):555-68. PubMed ID: 27083916
[TBL] [Abstract][Full Text] [Related]
17. Spotlight on elotuzumab in the treatment of multiple myeloma: the evidence to date.
Weisel K
Onco Targets Ther; 2016; 9():6037-6048. PubMed ID: 27785050
[TBL] [Abstract][Full Text] [Related]
18. Elotuzumab enhances natural killer cell activation and myeloma cell killing through interleukin-2 and TNF-α pathways.
Balasa B; Yun R; Belmar NA; Fox M; Chao DT; Robbins MD; Starling GC; Rice AG
Cancer Immunol Immunother; 2015 Jan; 64(1):61-73. PubMed ID: 25287778
[TBL] [Abstract][Full Text] [Related]
19. Elotuzumab: First Global Approval.
Markham A
Drugs; 2016 Mar; 76(3):397-403. PubMed ID: 26809244
[TBL] [Abstract][Full Text] [Related]
20. Profile of elotuzumab and its potential in the treatment of multiple myeloma.
Liu YC; Szmania S; van Rhee F
Blood Lymphat Cancer; 2014 Jun; 2014(4):15-27. PubMed ID: 26005365
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
